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Abstract
Background: The aim of this study is to evaluate the clinical efficacy and safety of transcatheter arterial
embolization (TAE) with N-butyl cyanoacrylate (NBCA) for the treatment of arterial esophageal bleeding in
esophageal cancer patients.
Methods: Between November 2008 and December 2014, five esophageal cancer patients underwent TAE with
NBCA for the treatment of arterial esophageal bleeding. We retrospectively evaluated the technical and clinical
success, recurrent bleeding, and procedure-related complications.
Results: All of the patients had bleeding from the esophageal artery and were in shock at the beginning of TAE.
Four patients had a coagulopathy at the time of TAE; however, the TAE could successfully arrest bleeding in all five
patients. After TAE, they immediately recovered from the shock state. Two patients were discharged without event,
one patient is currently hospitalized for another complication, and the other two patients died due to multiorgan
failure. In addition, no procedure-related complications such as esophageal infarction and recurrence of arterial
esophageal bleeding were observed during this study.
Conclusions: TAE with NBCA can arrest bleeding in esophageal cancer patients with active arterial esophageal
bleeding, even in those with a pre-existing coagulopathy.
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Background
Esophageal cancer patients may suffer lethal esophageal
artery bleeding [1]. Conventionally, the traditional first
line of therapy for intraesophageal bleeding from the
esophageal artery is an endoscopic procedure [2] and
that for intrapleural bleeding is surgery [3]. However,
with the advancement of technology, transcatheter arter-
ial embolization (TAE) of the esophageal artery can be
an effective alternative treatment [4–7]. It was reported
that TAE was useful for the treatment of endoscopically
unmanageable non-variceal upper gastrointestinal bleed-
ing, and there was some possibility of rebleeding due to
coagulopathy [8].
N-butyl cyanoacrylate (NBCA) has been used for many
years as a liquid embolic material and was demonstrated
to be useful for various diseases and conditions [9–16].
An advantage of TAE with NBCA is its high success rate
of occlusion even in patients with a coagulopathy; how-
ever, there are disadvantages that NBCA could cause
ischemic injury and is difficult to handle precisely [17].
We report the clinical efficacy and safety of TAE with




The protocol of this retrospective study was approved by
the research ethics board of the Gunma University
Hospital without the need for informed consent.
Between November 2008 and December 2014, five
patients underwent TAE for the treatment of arterial
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esophageal bleeding at our institution. All of the patients
were male, ranging in age from 66 to 77 years (mean
age, 71 years). All patients had esophageal cancer. Four
patients had undergone surgery for esophageal cancer,
and the fifth patient had undergone photodynamic therapy
(PDT). Patients who had undergone surgery developed
arterial esophageal bleeding 1 day, 10 days, 3 months, and
8 years after the surgery, respectively. The patient who had
undergone PDT developed arterial esophageal bleeding
2 days after the PDT.
Procedure
We used NBCA (Histoacryl; B. Braun, Melsungen,
Germany) as the embolic material in all five patients.
NBCA was chosen because the majority of patients had
a coagulopathy and were in an unstable condition.
Before angiography, if possible, we performed enhanced
computed tomography (CT) to confirm the extravasation
and the location of the esophageal artery; if it was not pos-
sible to perform enhanced CT, we checked previously
obtained enhanced CT scans. We performed diagnostic
angiography to localize the bleeding site after common
femoral artery puncture. If we failed to find the bleeding
site on aortography, we performed selective angiography
of the esophageal artery directly from the aorta with a 5-
Fr Michelson catheter (Medikit Co. Ltd., Tokyo, Japan),
intercostal artery, bronchial artery, or left inferior phrenic
artery. After confirming the active bleeding site, we
advanced a microcatheter (Estream 2.0; Toray Medical
Co. Ltd., Tokyo, Japan) as close as possible to the bleeding
site in the esophageal artery. Next, we mixed NBCA with
iodized oil (Lipiodol; Andre Guerbet, Aulnay-sous-Bois,
France) at a ratio ranging from 1:1.5 to 1:3. Prior to injec-
tion of the NBCA mixture, we flushed the microcatheter
with 5 % dextrose solution to prevent premature
polymerization of the mixture within the microcatheter.
We injected the NBCA mixture using a 2.5 mL syringe
under fluoroscopic monitoring. Next, we performed post-
embolization angiography to evaluate the effectiveness of
the treatment.
We retrospectively evaluated the technical and clinical
success of TAE, recurrent bleeding, procedure-related
complications, and clinical outcomes of each patient.
We defined technical success as successful superselection
of the bleeding vessel and delivery of the NBCA mixture,
as well as an angiographic result after embolization that
showed no evidence of active bleeding (i.e., the presence
of a pseudoaneurysm or extravasation of the contrast
agent). We defined clinical success as clinical improve-
ment without evidence of bleeding (i.e., clearing of the
nasogastric aspirate and stabilization of the hemoglobin
level). Patients who met one of the following criteria were
considered to have a coagulopathy: a prothrombin ratio of
greater than 1.5, a partial thromboplastin time of greater
than 45 s or a platelet count of less than 80,000/μL.
Complications were evaluated according to the Common
Terminology Criteria for Adverse Events v4.0 (CTCAE).
Results
The clinical and angiographic data of the five patients
with arterial esophageal bleeding are summarized in
Table 1. The example case is shown in Fig. 1. We diag-
nosed four of the five patients with coagulopathy from
hemorrhagic shock at the time of embolization. Before
TAE, enhanced CT was performed in all patients. In the
four patients, the esophageal artery was identified as a
branch of the aorta by referring to a past CT scan. All
the patients had a bleeding esophageal artery that origi-
nated directly from the aorta. Two of the five patients
had an esophageal artery that originated in a common
trunk with the right bronchial artery. The angiographic
findings in the four patients indicated extravasation of
the contrast agent, and two of the five patients had
pseudoaneurysm of the esophageal artery. After
embolization, each patient showed clearing of the naso-
gastric aspirate and stabilization of the hemoglobin level
without additional transfusion, and in turn, achieved
technical and clinical success. Further, there was no
evidence of symptomatic esophageal infarction or
other major complications directly related to NBCA
embolization in any of the patients. One patient
suffered cardiopulmonary arrest before TAE The pa-
tient could be resuscitated and TAE was completed;
however, he died due to multiorgan failure 6 days
later. Another patient died due to other underlying
conditions. This patient developed sepsis and multi-
organ failure 2 months after TAE. The other three
patients continue to undergo regular follow-up and
they have had no complications from TAE to date.
Discussion
NBCA has been used for many years as a liquid embolic
material and was demonstrated to be useful for occlu-
sion of cerebral arteriovenous malformation and fistula
[9], hemorrhage of visceral arteries [10–13], percutan-
eous transhepatic portal embolization prior to partial
hepatectomy [14], varicocele embolization [15], and type
2 endoleak embolization after stent-graft repair [16].
NBCA is a monomeric liquid adhesive that polymer-
izes in the presence of ionic solution, such as blood. It
polymerizes rapidly and forms a glue cast that strongly
adheres to the tissue. The polymerization time of NBCA
is controlled by addition of Lipiodol [18, 19], and it was
reported that some degree of mural inflammation due to
the embolization with NBCA to act in synergy with the
embolizing substance to render permanent occlusion [20].
An advantage of TAE with NBCA is its high success
rate of occlusion even in patients with a coagulopathy.
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Several reports have described the relationship between
coagulopathy and the outcome of transcatheter arterial
embolization with particles and coils for acute intestinal
bleeding [10, 21–23]. In the article by Jae et al. [24], the
clinical success rate of TAE in the group of patients with
coagulopathy was 83 % (15/18). They concluded that
TAE with NBCA is a highly effective and safe treatment
modality for nonvariceal upper gastrointestinal bleeding,
especially when it is not possible to advance the micro-
catheter to the bleeding site and when the patient has a
coagulopathy [24].
Among our cases, hemorrhage from the esophageal
artery was confirmed in the intraesophageal region in
two cases and in the intrapleural region in four cases.
One patient was scheduled to undergo esophageal cancer
surgery and was receiving PDT. The most common
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Fig. 1 Arterial esophageal bleeding in case 2. a Enhanced CT shows that contrast material was in the esophagus in the arterial phase, indicating
extravasation of contrast material (arrow). b Enhanced CT with angiography of the esophageal artery shows contrast material extravasation in
the esophagus (arrow). c An image of digital subtraction angiography of the esophageal artery demonstrates punctate contrast material
collections in the esophagus (arrow). d After transcatheter arterial embolization with a mixture of N-butyl cyanoacrylate (NBCA) and Lipiodol (arrow),
active bleeding improved
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significant adverse event after PDT is esophageal stricture
formation [25], hemorrhage induced by PDT has not been
reported.
The other patients were postoperative when arterial
esophageal bleeding occurred. Out of four patients, two
patients had esophageal bleeding in early postoperative
period and were confirmed the increase of bloody drain-
age in chest tube. The obvious reason for esophageal
bleeding was not clear; however, out of five patients, two
patients had radiation therapy and we thought radiation
therapy could be a risk for esophageal bleeding in pre-
operative and postoperative period. Treatment of esopha-
geal bleeding with TAE with NBCA in patients with
postoperative esophageal cancer has not been reported.
The typical complications of surgery such as hemorrhage
cannot be completely eliminated, and severe hemorrhage
is a rare and potentially lethal complication after esopha-
gectomy [1, 26].
In general, the traditional first-line treatment for
hemorrhage in the intraesophageal region is an endo-
scopic procedure [2]. In our cases, two patients had
hematemesis and one patient underwent the endoscopic
procedure; however, the esophageal bleeding could not
be controlled. Postoperative intrathoracic hemorrhage
after esophagectomy is usually treated by reoperation.
Indications for emergency thoracotomy for hemothorax
include the following: bleeding through the chest drain
at >100 ml/h for ≥5 h, or inability to maintain a normal
blood pressure without blood transfusion [3]. Generally,
reoperation is indicated; however, it is often difficult to
reoperate due to the patient’s condition such as shock,
disseminated intravascular coagulation, and so on.
Among our cases, two patients had bleeding in early
postoperative period and the management for the bleed-
ing were discussed between surgeons and interventional
radiologists, and TAE was selected as less invasive
method. A criterion for TAE in patients with hemotho-
rax is that extravasation is confirmed on contrast-
enhanced computed tomography [27]. Among our cases,
extravasation was confirmed by contrast-enhanced com-
puted tomography before TAE in four cases and the dif-
ferentiation between venous and arterial bleeding was
done with it. Before the report by Park et al. [17], there
were a few case reports about embolization treatment
for the esophageal artery [4–7]. Similar to the result by
Park et al., we succeeded in treating all the five patients,
although four patients had an underlying coagulopathy
at the time of the TAE.
Prior to performing emergent TAE, it is important to
find information about the arterial blood supply of the
esophagus. Branches of the subclavian, thyroidea ima,
common carotid, or superior thyroid arteries may also
supply the cervical esophagus. Branches of the right
third or fourth intercostal arteries may also supply the
midthoracic esophagus. Lastly, branches from the celiac,
splenic, short gastric, or left hepatic arteries may supply
the distal esophagus [5, 28]. About the patients with
esophageal cancer, by enhanced computed tomographic
scans, how much the esophageal artery was preopera-
tively identified has not been reported. Among our
cases, the esophageal artery was identified with past
computed tomographic scans in two cases. Before TAE,
interventional radiologists can predict from where the
bleeding esophageal artery originates by looking at past
computed tomographic scans.
Our study has several limitations. First, the study
population was small because arterial esophageal bleed-
ing in esophageal cancer patients is very rare and this
study was retrospective. Second, the observation period
was short and we cannot predict the long-term progno-
sis. Third, this study was not organized as the compara-
tive study between TAE with NBCA and TAE with other
embolic materials.
With the advancements in microcatheters and embolic
agents, TAE is becoming more important and effective
in the treatment of hemorrhagic diseases. At present, it
is not well known that esophageal bleeding in esophageal
cancer patients can be managed by TAE.
Conclusions
We reported the clinical efficacy and safety of TAE with
NBCA for the treatment of arterial esophageal bleeding
in esophageal cancer patients. We suggest that TAE with
NBCA can be an effective option for arterial esophageal
bleeding in esophageal cancer patients whether the
hemorrhage is in the intraesophageal region or the intra-
pleural region. Interventional radiologists, surgeons, and
emergency physicians should be aware of the usefulness
of TAE with NBCA to arrest bleeding from the esopha-
geal artery.
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